Continuous, Real-Time Tissue Oxygen Monitoring — Directly at the Point of Care
Lumee™ Oxygen provides intra-operative and 28-day post-operative tissue oxygen data for Critical Limb Ischemia patients. CE Mark targeted April 2026.
>$10.5B
Global TAM in tissue & pulse oximetry oxygen monitoring by 2030
500M+
People globally living with diabetes — growing 45% by 2050
85
Global patents granted or pending, backed by $100M+ in investment including $30M from DARPA
Platform
One Injectable Sensor.
Three Transformative Platforms.
The Profusa Lumee™ platform uses a biologically compatible injectable hydrogel microsensor — smaller than a grain of rice — to continuously monitor body chemistry from inside the tissue.
01
Oxygen Platform
Lumee™ Oxygen
Real-time tissue oxygen monitoring for CLI, wound care, and remote patient management.
Learn more →
02
Glucose Platform
Lumee™ Glucose
Continuous glucose monitoring up to 270 days via simple needle injection.
Learn more →
03
Data Platform
Data Discovery Platform
AI backbone linking real-time biochemistry to clinical insight, EMR data, and physician coaching portals
Learn more →